Nuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage

MT Newswires Live11-14

Nuvectis Pharma (NVCT) said Thursday its phase 1b trial to evaluate NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer demonstrated antitumor activity, including tumor shrinkage.

"The antitumor activity observed despite patients' advanced disease and extensive pre-treatment, while controlling for thrombocytopenia, is promising," said Ron Bentsur, CEO of Nuvectis.

The company expects to report additional clinical data from the trial in Q2 of next year, Bentsur said.

NXP800 was granted orphan drug designation by the US Food and Drug Administration in August.

Nuvectis Pharma shares were 54% lower in recent premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483809007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483809007","market":"hk","top_or_hot":-1,"title":"Nuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage","media":"MT Newswires Live","content":"<html><body><p> Nuvectis Pharma (NVCT) said Thursday its phase 1b trial to evaluate NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer demonstrated antitumor activity, including tumor shrinkage.</p><p>\"The antitumor activity observed despite patients' advanced disease and extensive pre-treatment, while controlling for thrombocytopenia, is promising,\" said Ron Bentsur, CEO of Nuvectis.</p><p>The company expects to report additional clinical data from the trial in Q2 of next year, Bentsur said.</p><p>NXP800 was granted orphan drug designation by the US Food and Drug Administration in August.</p><p>Nuvectis Pharma shares were 54% lower in recent premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nuvectis Pharma (NVCT) said Thursday its phase 1b trial to evaluate NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer demonstrated antitumor activity, including tumor shrinkage....</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483809007","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483809007","pubTimestamp":1731594742,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nuvectis Pharma  said Thursday its phase 1b trial to evaluate NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer demonstrated antitumor activity, including tumor shrinkage.\"The antitumor activity observed despite patients' advanced disease and extensive pre-treatment, while controlling for thrombocytopenia, is promising,\" said Ron Bentsur, CEO of Nuvectis.The company expects to report additional clinical data from the trial in Q2 of next year, Bentsur said.NXP800 was granted orphan drug designation by the US Food and Drug Administration in August.Nuvectis Pharma shares were 54% lower in recent premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NVCT":"Nuvectis Pharma, Inc."},"translate_title":"Nuvectis Pharma称抗癌药物NXP800试验显示肿瘤缩小","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCT":1},"content_text":"Nuvectis Pharma (NVCT) said Thursday its phase 1b trial to evaluate NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer demonstrated antitumor activity, including tumor shrinkage.\"The antitumor activity observed despite patients' advanced disease and extensive pre-treatment, while controlling for thrombocytopenia, is promising,\" said Ron Bentsur, CEO of Nuvectis.The company expects to report additional clinical data from the trial in Q2 of next year, Bentsur said.NXP800 was granted orphan drug designation by the US Food and Drug Administration in August.Nuvectis Pharma shares were 54% lower in recent premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483809007"}